Clinical Trial Update: Dual Thrombolytic Therapy With Mutant Pro-urokinase and Low Dose Alteplase for Ischemic Stroke [Phase 2]

View source ↗

Summary

Phase 2 trial examining dual thrombolytic therapy with mutant pro-urokinase and low-dose alteplase for ischemic stroke has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Stroke

Drugs mentioned

• Alteplase (alteplase)
• mutant pro-urokinase

Snippet

Sponsor: Erasmus Medical Center | Conditions: Ischemic Stroke | Phase 2 | Status: COMPLETED